Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000725083 | SCV000333863 | uncertain significance | not provided | 2016-07-08 | criteria provided, single submitter | clinical testing | |
Illumina Laboratory Services, |
RCV000400290 | SCV000388984 | uncertain significance | Autosomal recessive limb-girdle muscular dystrophy type 2N | 2018-01-13 | criteria provided, single submitter | clinical testing | This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score, this variant could not be ruled out of causing disease and therefore its association with disease required further investigation. A literature search was performed for the gene, cDNA change, and amino acid change (if applicable). No publications were found based on this search. This variant was therefore classified as a variant of unknown significance for this disease. |
Gene |
RCV000725083 | SCV000528156 | likely benign | not provided | 2020-11-02 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001079001 | SCV001014359 | likely benign | Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A2; Muscular dystrophy-dystroglycanopathy (congenital with intellectual disability), type B2; Autosomal recessive limb-girdle muscular dystrophy type 2N | 2023-12-27 | criteria provided, single submitter | clinical testing | |
Ce |
RCV000725083 | SCV005329784 | likely benign | not provided | 2024-08-01 | criteria provided, single submitter | clinical testing | POMT2: BP4, BP7 |